The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here.
I have been a holder here a for a while. I invested because the products this company makes has a real potential to save lives. Apart from their COVID test which is awaiting approvals in key markets they have large partners for, they are making a POC system. They have successfully made tests for HCV and antibiotic induced hearing loss which affects 1 in 500 children given gentamicin. The will profoundly benefit a large number of people. I don’t give carp what the trollers here say, or if the share price drops further because people are selling COVID stocks to buy cinema and airline stocks. I want the company to succeed because, as COVID has shown, it’s the right product and the world needs it....
Hi Ct, good to see you back! I agree, if someone is not invested and is only posting to talk a share dow, then they’re simply trolling - not nice. Legitimate concerns are important to talk about openly, same about strategy. But calling into question the integrity, capability or the character of the CEO is disrespectful and doesn’t reflect informed discussion.
u696061, yes agree the communication has been very poor, to be fair it always has been with GDR over the 4 years I've held my investment, but they have delivered broadly in line with where they have said they would be. Here the lack of communication is down to lack of approvals, we are stymied until those come in. They will come in and this will explode with sales :)
https://uk.mobile.reuters.com/article/amp/idUKKBN27S1II?__twitter_impression=true
Testing will still be needed once vaccines are widely used. That’s because no inoculation is likely to work all the time, and immunity may not last. Health professionals will need to be regularly checked. The World Health Organization estimates there are some 60 million front-line medical staff globally. Test them once a week, and you need 3.1 billion tests a year, costing, at five dollars a pop, $15.6 billion.
Testing may also be needed where people are confined for long periods, such as air travel, especially during outbreaks. If just 10% of the roughly 4.1 billion passengers each year were tested, the annual cost would be $2 billion. That implies at least 3.5 billion tests a year, costing $17.6 billion.
cut an paste from the report but interesting headline figures for spending values in this sector.. IQAI have several products to multiply
1. 41% of responding life sciences companies invested between $20 million and $50 million in AI during 2019.
2. 21% spent more than $50 million on the emerging technology.
3. 50%-plus intend to keep spending this year as AI “moves from tactical improvements in efficiency to larger-scale, organization-wide projects,” Deloitte reports.
4. 46% seem to accept that the time window for enjoying a return on AI investment takes longer than they’d expected.
Same pattern as the other day, not saying its US investors in the afternoon, but is it US investors in the afternoon? IB is a US business and will get much more visibility there than here. It's why I think a NASDAQ listing may happen, more scope for trading volume than over here although we don't do too badly!
I do see parallels which is why I'm invested in both. Covid aside, Genedrive has the opportunity to become a common point of care platform for qPCR. They've proved it now with a number of tests. I think however, they need a larger parent company and trade sale must be on the cards - but to be fair I've been saying that for a few years! For me it's about laying foundations and then building, the foundations are down and the business will be built, Covid has been a distraction but whilst here they need to deliver. They will, I'm confident.
the breadth of algorithms being deployed by IB is phenomenal, each gaining FDA approval which is not insignificant... The latest was an interesting partnership strategy as IB now proficient at the FDA process. Sales coming in now, the next 12 months is exciting. In terms of market cap, surely £100m-£200m with sales and a trade sale or NASDAQ float to exit...
Dream, I've been a share holder there since the end of 2018. I have had to sit through the same nonsense of 'there's no product', 'where's the value', 'sell now'. And indeed I did, took advantage of the drop and am sitting happy when, after 12 months, more news did recently drop around as it happens, FDA approvals. So, same story, greta products, takes time for approvals, but when they come they open many doors. Hold tight.
Sneak, it's a tough call for the business. As I said, they were not in the same industry as NCYT in delivering high volume tests to the market, they were. DB has to be given some credit in having a strategy that separated the competition and attracted a large partner to the table. They have to get approvals first and the MC reflects that.
In terms of small contract, GDR are not a B2C company. They want to make large batches of tests and sell them to a few resellers. I'm still optimistic, but I release that's not a typical way of thinking. Glass half empty is still a glass half full.
Flying, I agree, a lot of us invested based on the non-covid tests, COVID has created a lot of noise but allowed the business to fund its main activities which was unexpected. I think it has probably distracted the team but opened a lot of doors and got Genedrive on the radar of a few US companies now.
RB, my understanding is the number of symptomatic cases of COVID-19 per 1000 participants at 7 days following the second vaccine and that this was 90% lower in those that received the vaccine compared to those that received the placebo. We do not know what the effect on asymptomatic patients were. This suggests these people were not tested and the results is based on symptoms only!! Very poor.
I'm not sure but it looks to be 1-3 at at time?
Yes sorry immunising.
CE-IVD were given in May, approvals for US and India went in end of June. We are 4 and a bit months in to systems that were overloaded with over 1700 kits looking for approval. Unfortunately this has swamped the system. The choice will be whether the GDR kit provided advantages that provide a market now. I personally think that market is even bigger than it was and likely to be around longer than we initially thought.
So many unanswered questions about the vaccine. No data on the longevity of protection, no data on whether it prevents infection and spread of infection and if its only symptoms that are suppressed, no data on performance in the most vulnerable groups since the only trials to date are in healthy 18-55 range - arguably the wrong group to be testing. And no data yet on whether suppressing the spread simply puts evolutionary pressure on a mutated genotype to spread, unencumbered by the vaccine and into a population now free to mix again.
No, testing needs will increase and time will show that.
Genedrive do need their brake now with approvals. I think there model of either high volume (US) or low resource (India) will shine through. Again their POC solution too should debut and perform better than the Optigene which has shown to have sensitivity issues in their trials.
Hold firm, LTHs time will come here.
Depends where the mutations occur. The Pfizer vaccine causes the muscles cell the artificial virus infects product lots of the spike protein. The body sees that as foreign and elicits an immune response creating antibodies that recognise the chemical signature (epitopes) on the protein surface. That depends on the structure of the protein. If the mutation or mutations change the way this protein is presented such as changing an amino acid, then the antibodies produced by the immune response may not recognise it and prevent the body from fighting the virus. Thats what happens with the common cold and influenza and why you get infected again and again and again and again and...